Molica Stefano
Department Hematology/Oncology, Medical Oncology Unit, Catanzaro, Italy.
Leuk Lymphoma. 2007 May;48(5):866-9. doi: 10.1080/10428190601126636.
Immunomodulating drugs belong to a new class of therapeutic agents that have immunomodulatory, antiangiogenic and antiproliferative effects. Although the basis of anti-tumour activity of immunomodulating agents are not clear, results of clinical trials have demonstrated impressive activity in certain hemalogical disorders such as multiple myeloma (MM) and myelodysplastic syndromes (MDS). The peculiar properties of immunomodulating agents prompted investigators to test their role in patients with chronic lymphocytic leukemia (CLL). The efficacy of single-agent thalidomide in refractory CLL is disappointing, although its combination with fludarabine seems promising. Lenalidomide, a thalidomide analogue, is showing anti-tumour activity with durable response in refractory CLL. These preliminary results represent the basis for investigating the potential of lenalidomide in association with established chemotherapy regimens or as maintenance therapy.
免疫调节药物属于一类新型治疗药物，具有免疫调节、抗血管生成和抗增殖作用。尽管免疫调节药物的抗肿瘤活性基础尚不清楚，但临床试验结果已表明其在某些血液系统疾病如多发性骨髓瘤（MM）和骨髓增生异常综合征（MDS）中具有显著活性。免疫调节药物的特殊性质促使研究人员测试其在慢性淋巴细胞白血病（CLL）患者中的作用。沙利度胺单药治疗难治性CLL的疗效令人失望，但其与氟达拉滨联合使用似乎前景可期。来那度胺是沙利度胺的类似物，在难治性CLL中显示出抗肿瘤活性且疗效持久。这些初步结果为研究来那度胺与既定化疗方案联合使用或作为维持治疗的潜力奠定了基础。
